Benefits of Using a Customs Broker for Bio/Med

The main benefits of using a customs broker for bio/med shipments are fewer holds, correct agency filings and faster release of time-sensitive cargo. A life science import broker files the U.S. Customs and Border Protection (CBP) entry together with the data that the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), the U.S. Department of Agriculture (USDA) and the U.S. Fish and Wildlife Service (USFWS) may require. For reagents, specimens, drugs and devices, that agency layer is where most delays start.

This guide explains what medical customs brokerage involves, which agencies regulate medical and life science imports, how a broker reduces delay risk, when pharmaceutical and hazardous goods need a specialist and how to choose a broker. It focuses on imports into the United States.

Navigating the complexities of life sciences shipments

Shipping pharmaceutical and life science products involves more regulatory checkpoints than most freight. A single import can need a CBP entry, an FDA product code, a CDC permit for an infectious material and a temperature plan that survives the time the shipment spends waiting for release. Each of those is owned by a different party, and each can stop the shipment.

Understanding life sciences shipments

Life sciences shipments cover pharmaceuticals, biologics, medical devices, diagnostic kits, laboratory reagents, research materials and biological specimens such as blood, plasma, tissue and cell lines. Many need validated temperature control and packaging that meets carrier and dangerous goods rules. They are also often small, high value and urgent, which makes a one-day hold expensive.

Compliance failures can lead to customs holds, FDA detention, refusal of admission, destruction or re-export at the importer's cost and lost study timelines. Efficient clearance is therefore part of product protection, not only an administrative task.

The value of experienced customs brokers

A customs broker is licensed by CBP to transact customs business on behalf of others. Under 19 CFR 111.2, a person needs a broker license to transact customs business for someone else, while importers may file for their own account. The FDA notes that customs brokers are the only persons authorized by U.S. tariff laws to act as agents for importers. In practice, a broker transmits the entry through CBP's electronic system, answers CBP and agency questions and manages the release.

What separates medical customs brokerage from general brokerage is agency knowledge. A broker who files for laboratories and drug sponsors every day knows which FDA product codes, affirmations of compliance and permits a shipment of antibodies, cell lines or catheters needs. That knowledge prevents the errors that cause most holds.

What are the benefits of using a customs broker for medical shipments?

The benefits of using a customs broker for medical shipments are accurate agency data, correct classification, faster release and someone accountable when a shipment is held. The broker turns the commercial invoice and product details into a compliant entry, flags missing permits before the flight and works the hold if one happens. For medical devices and pharmaceuticals, the broker also carries the FDA admissibility data that general freight often lacks.

• Agency filings done once and correctly: FDA, CDC, USDA and USFWS data is transmitted with the CBP entry rather than chased after arrival.

• Classification and duty accuracy: correct Harmonized Tariff Schedule (HTS) numbers set duty rates and flag the agencies that must review the entry.

• Lower delay risk: pre-arrival review catches missing documents while there is still time to fix them.

• Cold chain protection: the broker and the carrier coordinate so release and delivery happen inside the product's shipping window.

• Audit readiness: entry records, classification rationale and permits are kept and retrievable.

• One point of contact: internal teams deal with one party instead of separate agencies.

B2B customs brokerage services for medical devices

B2B customs brokerage services for medical devices focus on FDA device data. For a foreign-made device, FDA's affirmation of compliance guidance for ACE lists the manufacturer's device registration number (DEV) and the device listing number (LST) as required in the standard import scenario, plus the premarket number (PM#), which can be a 510(k), De Novo or PMA number, when the device needs premarket clearance or approval. FDA states that declaring a code that is not on its valid list causes an entry rejection. A broker who files device entries regularly keeps these numbers in the product profile so each entry matches the FDA listing. Secure medical equipment customs brokerage services also cover high-value instruments, which may arrive as freight and need careful delivery after release.

Which agencies regulate medical and life science imports?

Medical and life science imports into the United States are regulated by CBP and several partner government agencies (PGAs). CBP controls the entry, duty and release. FDA regulates drugs, biologics, medical devices and other FDA-regulated products. CDC regulates infectious biological agents, infectious substances and vectors through its Import Permit Program. USDA's Animal and Plant Health Inspection Service (APHIS) regulates animal-origin materials and organisms that can affect livestock or poultry. USFWS regulates wildlife and wildlife products. The Drug Enforcement Administration (DEA) controls imports of controlled substances.

The table below summarizes when each agency is usually involved and what the broker files or checks. Product-specific exceptions apply, so confirm each case against the agency's own rules.

The key point is that each agency acts independently. A CDC permit, for example, does not satisfy a USDA permit requirement for the same material. That separation is stated directly in the CDC rule.

Regulatory compliance for pharmaceutical and medical device shipments

For pharmaceutical shipments and devices, FDA admissibility depends on the data submitted with the entry. FDA's entry submission guidance lists the product code, product description, country of production, manufacturer, shipper, importer and delivered-to party, contact details and, in some cases, affirmations of compliance. FDA also states that inaccurate or incomplete information may delay review. After screening, an entry may proceed, be examined or sampled, or be detained and later released or refused.

Clinical trial material, research-use reagents and commercial product often need different data and different declarations. A broker who knows which pathway applies avoids filing a research reagent as a finished drug, or the reverse.

CDC, USDA and wildlife permits

Under 42 CFR 71.54, a person may not import an infectious biological agent, infectious substance or vector into the United States without a CDC permit, unless an exclusion applies. Exclusions include diagnostic specimens not known or suspected to contain an infectious agent, when accompanied by an importer certification statement, and products cleared or approved under the Food, Drug, and Cosmetic Act. Bat and nonhuman primate specimens are excluded from that diagnostic specimen exception.

APHIS requires a permit for organisms and vectors under 9 CFR 122.2, and its Veterinary Services program also regulates animal products and by-products. Wildlife imports need a Form 3-177 declaration under 50 CFR 14.61. Our guide to import permits for US trade compliance covers the permit types in more detail.

DSCSA compliance and pharmaceutical traceability

The Drug Supply Chain Security Act (DSCSA) sets electronic, package-level traceability requirements for prescription drugs moving through the U.S. supply chain. FDA phased in the enhanced requirements with exemptions for different trading partner types, and it has extended the exemption for small dispensers to November 27, 2027, according to its DSCSA exemptions page. DSCSA is a distribution requirement rather than a customs filing, but importers of finished prescription drugs need their serialized data and transaction records in order before product enters distribution. See our DSCSA guide for pharmaceutical shippers for the current obligations.

How does a customs broker reduce delays for bio/med imports?

A customs broker reduces delays for bio/med imports by fixing problems before the shipment arrives. The broker reviews the invoice, product details and permits before departure, confirms the HTS number and agency flags, transmits the entry and agency data early and monitors the status until release. When a hold happens, the broker already knows the shipment and can respond to CBP or FDA immediately.

Preventing customs delays

Most delays come from a small number of avoidable causes:

1. Vague product descriptions: "lab samples" or "reagents" without composition, intended use or species of origin invites questions from every agency.

2. Missing or mismatched FDA data: a product code that does not match the product, or a device listing number that does not match FDA records.

3. Missing permits: a CDC permit, APHIS permit or importer certification that was not arranged before departure.

4. Wrong importer details: an importer of record without an active CBP identification number, a bond or a signed power of attorney.

5. Inconsistent paperwork: different values, quantities or descriptions on the invoice, air waybill and packing list.

Customs broker services for lower delay risk work through that list before the flight. For more on the causes, see our article on preventing customs delays in bio/med shipping.

Expedited medical customs brokerage

Expedited medical customs brokerage means the entry is ready before the cargo is. Pre-arrival filing lets CBP and FDA screening start while the shipment is in the air. Some shipments can also qualify for an informal entry, which 19 CFR 143.21 allows for shipments of merchandise valued at up to $2,500, with exceptions, though agency requirements still apply. Efficient medical customs brokerage also uses saved product profiles for repeat shipments, so the same reagent or kit is described the same way every time.

Customs documentation and paperwork

Bio/med entries usually need a commercial invoice with a precise description and value, a packing list, the air waybill and any permits or certifications. Depending on the product, that can include the CDC permit or importer certification, an APHIS permit, a USFWS declaration or DEA documents.

Two corrections to common assumptions help. First, FDA Prior Notice is a food requirement. FDA's entry guidance ties Prior Notice to food products, so drugs, biologics and devices go through FDA entry review with product codes and affirmations of compliance instead. Second, the 510(k) is not irrelevant to customs. It is a premarket submission, but its number can be required as the PM# affirmation of compliance on a device entry, so the broker needs it.

Tariff classification and duties

Correct classification is both a compliance requirement and a cost control. The HTS determines the duty rate and also signals which agencies must review the entry. For example, HTS heading 3822 covers prepared diagnostic or laboratory reagents, heading 3002 covers human blood, antisera and immunological products, and heading 9018 covers medical, surgical, dental and veterinary instruments and appliances. The exact number depends on composition and use, so treat these as starting points and check the Harmonized Tariff Schedule or a binding ruling for each product.

A broker documents the classification rationale for each product, applies any duty programs that fit and keeps the decision consistent across entries. Our guide to HS codes for healthcare and life sciences covers the approach in more detail.

Do pharmaceutical and hazardous goods need a specialized customs broker?

Pharmaceutical and hazardous goods do not legally require a specialist beyond a licensed broker, but in practice they benefit from one. The entry has to carry FDA data, may need DEA or CDC authorization and has to match a shipment that is also regulated as dangerous goods. A broker who understands those overlaps prevents the mismatch between the customs description and the dangerous goods description that triggers questions.

Hazardous goods pharmaceutical customs brokerage

Hazardous goods pharmaceutical customs brokerage covers shipments that are both FDA-regulated and dangerous goods, such as products shipped on dry ice, flammable solvents in kits or infectious specimens shipped as UN3373. Dangerous goods packing, marking and documentation follow IATA and 49 CFR rules that are separate from customs. The broker does not pack the shipment, but it does need the classification to describe the goods consistently and to anticipate permits. For the transport side, see our guide to classifying biological shipments.

Controlled substances and research compounds

Controlled substances in Schedule I or II, and certain others, may not be imported without DEA registration and a DEA permit under 21 CFR 1312.11. Research compounds that are controlled, or close analogues, need early review. A broker who sees a controlled substance on an invoice should stop the shipment before departure, not after arrival.

Temperature control and secure handling

Many pharmaceutical and biological products must stay within a validated temperature range. Customs time counts toward the shipping window, so clearance planning is part of the cold chain plan. FDA monitoring expectations are explained in our article on FDA temperature monitoring rules.

Customs brokerage shipping coordination

Customs brokerage shipping coordination means the broker, the carrier and the consignee work from the same plan. The broker knows the flight and the arrival time, the carrier knows the entry status and the consignee knows when to expect delivery. If an exam is likely, the team can arrange dry ice replenishment or controlled storage in advance. A customs brokerage shipping coordination system platform that shows entry status and transport events together makes those handoffs visible.

For the most time-critical materials, onboard courier services keep a trained person with the shipment through clearance and delivery, which maintains an unbroken chain of custody.

Secure medical customs brokerage

Secure medical customs brokerage protects both the cargo and the data. Entry data includes patient-adjacent information for some specimens, product details for unreleased drugs and commercial values. Ask how the broker controls access to entry records, how documents are exchanged and who can see shipment status.

Technology: ACE filing and integrated visibility

CBP's Automated Commercial Environment (ACE) is the system in which import entries are made, including the FDA data and affirmations of compliance that FDA lists for ACE entries. FDA's entry guidance describes brokers transmitting FDA data through the Automated Broker Interface (ABI), CBP's electronic import processing system. That electronic flow is why data quality matters so much: FDA screens the transmitted data before anyone opens the box.

How do digital customs brokerage platforms improve accuracy and speed?

Digital customs brokerage platforms improve accuracy and speed by reusing validated product data, checking entries before transmission and showing status in real time. A saved product profile with the correct HTS number, FDA product code and affirmations reduces retyping errors. Pre-transmission validation catches missing fields. Status updates show when an entry is released, held or under FDA review, so the team can act the same day.

Advantages of integrating customs brokerage into logistics software

The advantages of integrating customs brokerage into logistics software are a single record for each shipment, fewer handoffs and earlier warnings. When transport events and entry status sit in the same view, a delayed flight and a pending FDA review are seen together, and the team can decide whether to replenish dry ice or reroute delivery. Integrated visibility platforms for healthcare shipments with customs and compliance needs are most useful when they show agency status, not only transport milestones.

Handling customs audits

CBP audits review classification, valuation and record keeping. For life science importers, a review can also touch agency compliance, such as whether permits were in place and whether FDA data was accurate. Brokers must retain powers of attorney with their records under 19 CFR 141.46, and a good broker keeps classification notes and permit copies with each entry. That file is what answers an audit question quickly.

International shipping and multi-jurisdiction compliance

Exports and imports into other countries add their own rules. The European Union regulates devices under its Medical Device Regulation and In Vitro Diagnostic Regulation, and Great Britain runs its own device registration. Destination rules for permits, labeling and importers of record vary by country and change over time. A broker network with in-country partners prepares destination documents in advance rather than learning the rules at the border.

The consequences of poor customs management

Poor customs management in life sciences compounds quickly. A hold can push a frozen shipment past its dry ice capacity, delay a clinical trial visit or stall a laboratory study. Repeated description or classification errors can draw more examinations on later entries. A refused shipment may have to be exported or destroyed at the importer's expense. A broker does not remove these risks, but it replaces ad hoc problem solving with a managed process.

How do you choose a life science import broker?

Choose a life science import broker by checking its license, its experience with the agencies your products trigger, its pre-arrival process and how it works with your carrier and cold chain team. Ask for examples of entries similar to yours and for a description of how it handled a recent FDA hold. The checklist below covers the main points.

• License and scope: med shipping is regulated work, so start with a licensed U.S. customs broker and a clear answer on who handles exports and non-U.S. entries.

• Agency experience: regular FDA, CDC, USDA and USFWS filings for products like yours.

• Onboarding: how it sets up the power of attorney, importer number and continuous or single-entry bond.

• Pre-arrival process: when it reviews documents and how it flags missing permits.

• Cold chain coordination: how it works with the carrier on timing, storage and dry ice during a hold.

• Technology: saved product profiles, status visibility and secure document exchange.

• Escalation: who answers after hours, and how fast.

Customs brokerage for healthcare shipments works best when the broker is engaged before the first shipment, not after the first hold.

How Mercury can help

Mercury's customs brokerage services for life sciences are built for regulated shipments such as pharmaceutical compounds, diagnostic kits, biological specimens, research materials and laboratory instruments. In the U.S., Mercury acts as customs broker through Mercury Customs Brokerage Services LLC after the importer signs a power of attorney, and it coordinates with partner brokers for exports and non-U.S. entries. Our article on why you need to sign a customs power of attorney explains that step.

Mercury completes customs pre-advisory documentation before a cold chain shipment moves and uses saved commodity profiles for repeat shipments. It can also act solely as your U.S. customs broker while you keep your own carrier. Mercury is ISO 9001:2015 certified, and because it handles both logistics and brokerage, the two sides of a shipment stay coordinated. For clinical trial logistics across several countries, that coordination helps keep investigational product moving on schedule.

Life science customs clearance keeps getting more detailed, with more data per entry and more agencies watching. Importers who bring in a specialized broker early spend less time on holds and more time on their programs.